[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asd":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,132,172,194,222,241,265,289,313,340,369,399,423,452],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100431550","trial-of-center-based-vs-in-home-pivotal-response-treatment-prt-in-autism-100431550",false,"NCT04899544","Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism","Randomized Controlled Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism","PRT-HvC","Inclusion Criteria:\n\n* Diagnosis of Autism Spectrum Disorder (ASD) based on Autism Diagnostic Interview Revised (ADI-R), Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) or Childhood Autism Rating Scale, Second Edition (CARS-2), Diagnostic and Statistical Manual 5th Edition (DSM-5), and expert clinical opinion;\n* Boys and girls between 2.0 and 5.11 years;\n* Ability to participate in the testing procedures to the extent that valid standard scores can be obtained;\n* Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5): Standard score at least 1 standard deviation below average for expressive language ability for 2 and 3 year olds; 2 standard deviations for 4 year olds, and 3 standard deviations for 5 year olds;\n* Stable treatment (e.g., Applied Behavior Analysis - ABA), speech therapy, school placement, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements;\n* No anticipated changes on treatment during study participation for Center-Based Pivotal Response Treatment (PRT-C) and In-Home Pivotal Response Treatment (PRT-H);\n* No more than 60 minutes of individual 1:1 speech therapy per week;\n* Availability of at least one parent or primary caregiver who can consistently participate in parent training and research measures.\n\nExclusion Criteria:\n\n* Current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.);\n* Receiving ABA of 15 hours or more;\n* Presence of active medical problem (e.g., unstable seizure disorder or heart disease);\n* Previous adequate Pivotal Response Treatment (PRT) trial;\n* Participants living more than 30 miles from Stanford University;\n* Child's primary language other than English.","ALL","2 Years","5 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this clinical trial is to compare the efficacy of a 16-week center-based Pivotal Response Treatment (PRT-C) versus home-based Pivotal Response Treatment (PRT-H) in targeting social communication deficits in young children with autism spectrum disorder (ASD) with significant language delay. The two groups will also be compared to a control group that consists of children who are receiving treatment as usual (TAU).",[28,29,30],"Autism","Autism Spectrum Disorder","ASD",[32,33,34,35],"pivotal response treatment","PRT","center based","social and communication","RECRUITING","2026-06-22",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2022-10-18",{"date":44,"type":22},"2028-09-15",{"name":46,"class":47},"Stanford University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":107,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":48},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"17 Years","99 Years",{"count":61,"type":22},1000000,[25],"BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[65,66,67,28,68,69,30,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106],"Asperger's Disorder","Asperger Disorder","Autism Disorder","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[108,109,110,111,112,113,114,115,116,117,118,119,120,121,122],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","NOT_YET_RECRUITING","2026-06-16",{"date":37,"type":40},{"date":127,"type":22},"2026-08-01",{"date":129,"type":22},"2028-12-31",{"name":131,"class":47},"Veterans Recovery Network Inc.",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":48},"100616348","phase-1-adia-med-of-winter-park-llc-autism-spectrum-disorder-research-study-100616348","NCT07304440","Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study","Inclusion Criteria:\n\n* Age 3-12 years\n* Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2)\n* Parent\u002Fguardian willingness to consider experimental treatments and comply with study requirements\n* Ability to attend all scheduled visits\n* Able to meet study cost requirements ($12,000 study fee plus bloodwork costs, if applicable) as described in the informed consent\n\nExclusion Criteria:\n\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days\n* Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening","3 Years","12 Years",{"count":141,"type":22},100,[143,144],"PHASE1","PHASE2","This 24-month study is testing whether adding AdiaVita, an umbilical cord blood-derived stem cell and exosome product, to glutathione therapy helps improve autism symptoms in children ages 3-12 more than glutathione alone. Children will be randomly placed into one of two groups for the first three months: one group receives glutathione only, and the other receives glutathione plus monthly intravenous AdiaVita infusions. Both groups also use topical glutathione cream twice daily at home. Autism symptoms will be tracked over two years using the Autism Treatment Evaluation Checklist (ATEC) filled out by parents and by therapists or teachers. Safety, side effects, quality of life, and overall well-being will be closely monitored through regular clinic visits, physical exams, blood tests, and adverse event reporting. After the initial three-month phase, children who received glutathione alone may cross over to receive AdiaVita infusions at no additional cost if safety checks at month 6 are satisfactory. Approximately 100 children with a confirmed autism diagnosis from the Central Florida area will take part. Participation is completely voluntary, and families may withdraw at any time.",[29,28,30,147],"Autism Spectrum Disorder (ASD)",[149,150,151,152,153,154,155,28,29,30,156,157,158,159,160,161,162,163],"Glutathione","Intravenous glutathione","Glutathione therapy","Antioxidant therapy","Oxidative stress","Immune modulation","Anti-inflammatory therapy","Autism symptoms","Stem cell therapy","MSCs","Mesenchymal stem cells","Regenerative medicine","Cellular therapy","Hematopoietic stem cells (HSCs)","Allogeneic stem cells",{"date":165,"type":40},"2026-06-17",{"date":167,"type":40},"2026-05-01",{"date":169,"type":22},"2028-06-15",{"name":171,"class":47},"Adia Med of Winter Park LLC",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":139,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":48},"100610373","phase-4-comprehensive-toileting-program-100610373","NCT07226739","Comprehensive Toileting Program","Comprehensive Toileting Programming: Enuresis Treatment to a Randomized Clinical Trial of a Caregiver-Mediated Multidisciplinary Intervention for Encopresis","Inclusion Criteria\n\n* Age 5 to 12\n* Diagnosis of an intellectual or developmental delay (excluding individuals with ADHD alone)\n* Encopresis (more than 1 incontinent BM a week)\n* Required for pre-randomization phase only: Enuresis (\\> 1 incontinent urination per day when on a consistent toileting sit schedule)\n* At least one caregiver who speaks and understands English\n\nExclusion Criteria:\n\n* Unresolved medical condition that would impede toilet training (e.g., interference with sphincter control, short gut syndrome, urinary tract or gastrointestinal infection, unexplained diarrhea, recent intestinal surgery, inflammatory bowel disease)\n* Failed intensive toileting treatment in the past 2 yrs with protocols akin to study\n* Current serious behavioral or psychiatric disorder that requires another treatment\n* Current or planned other intervention (behavioral or medical) for incontinence",{"count":180,"type":22},150,[182],"PHASE4","The current study aims to monitor fecal continence after autistic youth complete enuresis treatment and for individuals who continue to experience encopresis after acquiring urine continence, evaluate a caregiver-mediated version of a Multidisciplinary Intervention for Encopresis (CM-MIE) delivered via telehealth to determine efficacy in a randomized clinical trial.",[185,30],"Encopresis",{"date":187,"type":40},"2026-06-18",{"date":189,"type":40},"2026-06-01",{"date":191,"type":22},"2031-01",{"name":193,"class":47},"Emory University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":219,"locationsCount":48},"100616869","genes-and-autism---induced-pluripotent-stem-cells-100616869","NCT07311213","GENES AND AUTISM - Induced Pluripotent Stem Cells","EXPLORATIONS CELLULAIRES - CELLULES PLURIPOTENTES INDUITES DES SUJETS PRESENTANT UN TSA, DE LEURS APPARENTES, ET DE TEMOINS","IPSC","Inclusion Criteria:\n\n● For all participants :\n\n* 1\\) Be Included in the \"Genes and Autism\" protocol (C07-33 or C16-89).\n* 2\\) Affiliated to the social insurance, Universal Health Coverage or any equivalent system.\n\n  →As a Reminder : C07-33 inclusion criteria\n\n  ● Participants with ASD.\n* 1\\) Autistic patients must meet the diagnostic criteria of DSM-IV \\[American Psychiatric Association, 1994\\] and the criteria of ADI-R (Autism Diagnostic Interview-Revised, Lord et al., 1994) and ADOS for autism.\n\n..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders.\n\n..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders\n\n* 2\\) Be at least 2 years old, with no upper age limit\n* 3\\) Somatic state compatible with blood test\n\n  ● Adult controls and adult relatives of controls\n* 1\\) Be between 18 and 65 years old\n* 2\\) Somatic and intellectual state compatible with blood test\n\n  ● Controls with mental retardation\n* 1\\) Minimum age of 2 yearsIQ \\\u003C 70Child controls\n* 2\\) Minimum age of 2 years\n\n  →As a Reminder : inclusion criteria C16-89\n\n  ● Probands with ASD\n* 1\\) Meet the diagnostic criteria for ASD of the of DSM-5 \\[American Psychiatric Association, 2012\\]. The diagnosis will be based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al, 2003) and those of the Autism Diagnosis Observational Scale (ADOS-2) (Lord et al, 1994)\n* 2\\) Be at least 24 months old with no upper age limit\n* 3\\) Somatic state compatible with a blood test\n* 4\\) Affiliation to the Social Insurance\n* 5\\) Signature of informed consent by the applicant or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship\n\n  ● Controls wihout ASD\n* 1\\) At least 24 months old\n* 2\\) Somatic and Intellectual state compatible with a blood test\n* 3\\) Affiliation in the Social Insurance\n* 4\\) Signature of informed consent by the subject or by holders of parental authority if the subject is a minor, or by the guardian if the subject is under guardianship\n\n  ● Relatives of the probands with ASD or of controls without ASD\n* 1\\) At least 24 months old\n* 2\\) Somatic and intellectual state compatible with blood test\n* 3\\) Affiliation to the Social Insurance\n* 4\\) Signature of informed consent by the subject or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship\n\nExclusion Criteria:\n\n* For all participants\n\n  * 1\\) Refusal to have a blood test\n  * 2\\) Medical illness (including psychiatric disorder) not yet fully stabilised and making participation in the study impossible\n  * 3\\) Person subject to a mesure of lagal protection\n  * 4\\) Known serology : VIH+ or VBH+ or VCH+\n\n    * As a reminder : exclusion criteria C07-33\n  * 1\\) For all participants : Severe Intelectual Deficiency (IQ,35 or developmental age \\\u003C18 months)\n  * 2\\) Controls : Neurological or psychiatric history other than mental retardation\n\n    o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982)\n\n    o History of epileptic episodes\n\n    o Immunosuppressive treatment or known immunoinflammatory disease\n\n    →As a reminder : exclusion criteria C16-89\n  * 1\\) Probands with Autism Spectrum Disorder\n\n    o Severe intellectual disability (IQ\\\u003C35 or developmental age \\\u003C18 months)\n  * 2\\) Controls (neurotypical development)\n\n    o Identified intellectual disorder or cognitive developmental disorder\n    * Personal psychiatric history of schizophrenia, bipolar disorder, substance use disorders (except tobacco), recurrent depression (\\>2 episodes, lifetime), severe unstabilized anxiety disorder\n    * History of epilepsy episodes or severe neurological disease\n  * 3\\) Relatives of the TSA applicants or controls\n\n    * Medical condition (psychiatric or somatic) not compatible with inclusion",{"count":203,"type":22},450,[25],"Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social interaction and verbal and non-verbal communication (DSM-5, 2013), affecting approximately 2% of the general population. In 5 to 40% of cases, genetic factors are identified as the cause of these disorders, with prevalence depending on the technique used (exomes and\u002For SNP arrays) and the associated intellectual deficit. In the majority of cases, the etiology remains unknown. Studies of microdeletions\u002Fmicroduplications (copy number variants) or Whole Exome Sequencing and Whole Genome Sequencing (Single Nucleotide Variants) show the involvement of numerous genes in the predisposition to autism. ASD remains a genetically heterogeneous disorder, as more than 250 genes have been associated with ASD to date.\n\nThe main objective of the project is to continue identifying genetic factors, and also to understand the biological mechanisms involved in the emergence of autistic symptoms.\n\nIdentifying biological pathways is an essential step in developing new therapeutic strategies. In addition, one of the major challenges of this study is to better understand the phenotype\u002Fgenotype relationships in ASD. This requires in-depth knowledge of the phenotypic characteristics of participants with ASD and their families, as well as neurotypical populations. This study combines the scientific expertise of researchers specializing in molecular biology, phenotypic exploration (clinical, cognitive, MRI, EEG, biochemistry, immunology), and the use of pre-therapeutic cellular models (iPSCs, neural precursors, organoids).\n\nThe objective of this work is the identification of numerous genes associated with ASD and involved in synaptic formation and regulation: NLGN3-4, SHANK1 and SHANK3, CNTN-6, and CNTNAP4. This work was combined with in-depth phenotypic explorations of ASD participants and their relatives. It has made it possible to clarify the neuroanatomical characteristics of participants with ASD and their genetic substrate, as well as the underlying cognitive processes.\n\nAll of this work opens up new prospects for identifying new therapeutic targets using preclinical cell models (IPSCs Induced pluripotent stem cells, neural progenitors, organoids) developed in particular by I-Stem and Human Technopole.",[67,30],[208,209,210,211,212],"autism","genes","phenotype","complex heritability","Induced pluripotent stem cells","2026-06-03",{"date":215,"type":40},"2026-06-05",{"date":127,"type":22},{"date":218,"type":22},"2041-08-01",{"name":220,"class":221},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100637682","phase-1-gaip-asd-research-study-100637682","NCT07622316","GAIP ASD Research Study","Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder Research Study","Inclusion Criteria:\n\n* Age 3 years and up\n* Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2 or its equivalent)\n* Parent\u002Fguardian willingness to consider experimental treatments and comply with study requirements\n* Ability to obtain required bloodwork\n* Ability to attend all scheduled visits\n\nExclusion Criteria:\n\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Immunocompromised\n* Malignancy history\n* Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days",{"count":141,"type":22},[143],"This clinical research study evaluates the safety and preliminary effects of AdiaVita (umbilical cord blood-derived stem cells and exosomes) combined with glutathione versus glutathione alone in people aged 3 and older with Autism Spectrum Disorder (ASD). In this randomized, participant-blinded crossover trial of about 100 participants, one group receives three monthly AdiaVita IV infusions plus glutathione, while the control group gets placebo saline infusions with the same glutathione regimen; the primary outcome is improvement on Autism Treatment Evaluation Checklist (ATEC) scores, with full safety follow-up through 12 months and optional crossover to AdiaVita for eligible controls. The treatment is investigational and not FDA-approved for autism, with no guaranteed benefit and risks including infusion reactions; participants pay $12,000 for the initial schedule, and all data remains confidential.",[29,28,30,147],[149,150,151,152,153,154,155,28,29,30,156,157,160,163,161],{"date":213,"type":40},{"date":189,"type":22},{"date":237,"type":22},"2027-06-30",{"name":239,"class":47},"Greater Atlanta Integrative Pediatrics",2,{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":48},"100568243","phase-2-spironolactone-improved-children-with-gene-mutations-related-to-ncor-100568243","NCT06678685","Spironolactone Improved Children With Gene Mutations Related to NCOR","An Exploratory Study of Spironolactone Tablets for the Treatment of Children With Gene Mutations Related to NCOR","Inclusion Criteria:\n\n1. ADOS-2 diagnostic criteria for autistic children\n2. Patients with NCOR related gene mutation detected by whole exon test;\n3. Age: 3-10 years old;\n4. The subject and (or) guardian sign the informed consent, agreeing that the researcher will cooperate with the clinical trial process and collect clinical data and peripheral blood and urine samples;\n\nExclusion Criteria:\n\n1. have other pathogenic mutations (confidence higher than the NCOR related mutation);\n2. Boys over 10 years old;\n3. Allergic to spironolactone, used spironolactone one month before enrollment;\n4. Hyperkalemia, serum potassium concentration \\> 5.5mmol\u002FL;\n5. Renal insufficiency;\n6. Used related drugs one month before enrollment: potassium supplement, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, digoxin, coletenamine, acetylsalicylic acid, abiraterone;\n7. Fever (body temperature above 37.3°);\n8. Clinically significant metabolic, hematological, liver, immune, urological, endocrine, neurological, pulmonary, psychiatric, skin, allergic, renal, or other major conditions in the determination of ASD that may affect the interpretation of study findings or patient safety.","10 Years",{"count":240,"type":22},[144,251],"PHASE3","MECP2, a key transcriptional regulator, has been shown to interact with the NCOR1\u002F2 complex to modulate gene expression. Specifically, MECP2 recruits the NCOR complex to specific genomic loci, facilitating histone deacetylation and chromatin remodeling, which are essential for the proper regulation of genes involved in synaptic function and neuronal maturation. Disruptions in the MECP2-NCOR interaction have been implicated in neurodevelopmental disorders, including Rett syndrome and autism spectrum disorder (ASD), highlighting the collaborative role of MECP2 and the NCOR1\u002F2 complex in maintaining neuronal homeostasis.\n\nBuilding on this, NCOR1\u002F2 constitutes the NCOR complex,interacts with many different nuclear receptors to produce special physiological effects. The receptors further recruit epigenome-modifying enzymes that are involved in the transcription of multiple genes involved in neurotransmission and synaptic plasticity. Studies of mice with gene knockout and autistic with NCOR mutations have found that both exhibit clinical symptoms characteristic of ASD, such as deficits in social interaction, spatial learning, and impaired recognition memory. Further study revealed that the cause was the hyperexcitability of GABAergic neurons in the lateral hypothalamus (LH) due to the NCOR1\u002F2 defect, which impaired synaptic plasticity in the hippocampal CA3 region through the single synaptic LHGABA-CA3 neural projection, and thus exhibited learning\u002Fmemory impairment. Therefore, drugs that affect the NCOR receptor can improve learning\u002Fmemory impairment by affecting GABA neurons. Spironolactone is a widely used diuretic with good safety. Spironolactone is widely used in the treatment of hypertension, edema, and anti-androgen therapy in children. Spironolactone is currently under investigation as a potential treatment for children with NCOR gene mutations. Preclinical studies have demonstrated that spironolactone can ameliorate ASD-related symptoms in NCOR mutant mice, including reduced sensorimotor capacity, learning disability, and impaired working memory. Furthermore, the efficacy of related diuretics in the treatment of ASD has been demonstrated clinically. Therefore, spironolactone may represent a novel therapeutic target for patients with NCOR-related gene mutations in the future.",[254,255,30],"NCOR Gene Mutations","Spironolactone","2026-05-14",{"date":258,"type":40},"2026-05-18",{"date":260,"type":40},"2024-10-30",{"date":262,"type":22},"2027-12-30",{"name":264,"class":47},"Qilu Hospital of Shandong University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":272,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":48},"100616307","phase-2-a-phase-2a-trial-of-dt402-for-autism-spectrum-disorder-100616307","NCT07303907","A Phase 2A Trial of DT402 for Autism Spectrum Disorder","An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)\n2. Male or Female aged 18 to 65\n3. Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66\n\nExclusion Criteria:\n\n1. Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking\n2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder\n3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)\n4. Any clinically significant unstable illness","18 Years","65 Years",{"count":275,"type":22},20,[144],"A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder",[29,30],"2026-03-31",{"date":281,"type":40},"2026-04-06",{"date":283,"type":40},"2025-12-03",{"date":285,"type":22},"2027-08",{"name":287,"class":288},"Definium Therapeutics US, Inc.","INDUSTRY",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":57,"sex":17,"minAge":138,"maxAge":19,"enrollmentInfo":296,"targetDuration":298,"studyType":299,"phases":4,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":311,"locationsCount":48},"100623734","differences-in-n-cad-concentration-and-brain-function-between-children-with-asd-and-td-100623734","NCT07400484","Differences in N-CAD Concentration and Brain Function Between Children With ASD and TD","A Study on the Differences in N-CAD Concentration and Brain Function Between Children With Autism Spectrum Disorder and Typically Developing Children","Inclusion Criteria:\n\n1. Age at enrollment ≥ 3 years and \\\u003C5 years;\n2. The diagnosis was made by 2 developmental behavioral pediatricians or child psychiatrists with vice senior titles or above, and the history and clinical manifestations were in line with ASD and ICD-11 diagnostic criteria for ASD; .\n\nExclusion Criteria:\n\n1. Diagnosis or manifestation of genetic diseases or syndromes related to ASD (such as Rett syndrome);\n2. Medical or nervous system diseases affecting growth, development or cognition (such as central nervous system infection, epilepsy, congenital heart disease, etc.);\n3. Sensory impairment such as vision or hearing loss;\n4. Low birth weight (birth weight \\\u003C2000 g) or preterm birth (gestational age \\\u003C37 weeks);\n5. Adopted children;\n6. Parents refused to sign the informed consent form;\n7. Other researchers consider it inappropriate to participate in the study.",{"count":297,"type":22},98,"1 Day","OBSERVATIONAL","The incidence of autism spectrum disorders is increasing, about 1 \u002F 36. Neural cadherin (NCAD) is closely related to synaptic structure and function. The cdh2 gene encoding NCAD has been shown to be associated with a variety of neurodevelopmental diseases and is one of the six risk genes for ASD. Functional near-infrared spectroscopy (fNIRS) is a neuroimaging technology that uses the principle of near-infrared spectroscopy to detect the functional activation of human cortex. The application of fNIRS to explore the neural mechanism of children with ASD has developed rapidly. It has the advantages of non-invasive, portable, relatively low cost and unlimited physical activity. And for ASD children, their command compliance and self-control are relatively low, so fNIRS is more widely used in ASD children. According to dsm-5 standard, we recruited ASD children and TD children, collected their peripheral blood, and detected the plasma n-cad concentration. At the same time, the resting state of fNIRS of the two groups of children was collected, and the ultra scan monitoring was carried out simultaneously during Gesell assessment. The purpose of this study was to explore the difference of peripheral blood NCAD concentration between preschool ASD children and TD children and the difference of brain function in resting state and social interaction state. And the relationship between the characteristics of brain function and the level of cognitive development in children with ASD.",[30],[30,303,304],"Neural cadherin","Functional Near-infrared Spectroscopy","2026-02-02",{"date":307,"type":40},"2026-02-10",{"date":309,"type":40},"2025-12-18",{"date":279,"type":22},{"name":312,"class":47},"Chen Li",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":321,"maxAge":58,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":48},"100621048","omega-3-autism-spectrum-disorder-asd-100621048","NCT07365553","Omega-3, Autism Spectrum Disorder (ASD)","Omega-3 Fatty Acids and Autism Spectrum Disorder (ASD) - A Double-blind Randomized Controlled Trial of Omega-3 Fatty Acids in Youth With ASD","OMeASD","Inclusion Criteria:\n\n* diagnosis of DSM5 ASD made by child and adolescent psychiatrist\n* age 6-17 years-old at the time of enrolment\n* no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks,\n* Signed informed consent.\n\nExclusion Criteria:\n\n* comorbid other psychiatric disorders, including schizophrenia or affective mood disorder (Bipolar and Major Depressive Disorder), or substance use disorder\n* comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders\n* currently using omega-3 supplements or probiotics\n* allergy to omega-3.","6 Years",{"count":323,"type":22},50,[25],"This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).",[30],[328,329,330],"inflammation","adolescent","omega-3","2026-01-16",{"date":333,"type":40},"2026-01-26",{"date":335,"type":40},"2022-07-15",{"date":337,"type":22},"2026-07-31",{"name":339,"class":47},"China Medical University Hospital",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":240},"100612858","testing-scalable-caregiver-interventions-for-autism-100612858","NCT07259044","Testing Scalable Caregiver Interventions for Autism","Global Strategies, Local Impact: Testing Scalable Caregiver Interventions for Autism in Low-Resource Health Systems","Inclusion Criteria:\n\n* Caregiver is willing to participate\n* Caregiver speaks either Swahili or English\n* Child is between 2 and 8 years of age\n* Child presents with concerns suggestive of autism\n\nExclusion Criteria:\n\n* The caregiver declines to participate\n* The child has significant vision or hearing impairment\n* The child is not primarily cared for by the enrolled caregiver","8 Years",{"count":349,"type":22},320,[25],"Autism spectrum disorder affects 1-2% of children worldwide, yet access to quality care remains limited, especially in underserved communities. Families face systemic barriers such as workforce shortages, high caregiver stress, and a lack of culturally appropriate services.\n\nTo address these gaps, researchers developed a group-based caregiver training program to improve caregiver well-being and child communication and behavior. Successfully piloted in rural U.S. communities and western Kenya through the AMPATH Program, the intervention showed promising results in reducing caregiver stress and autism severity.\n\nBuilding on this success, a new study will evaluate two delivery models-professionally-led and peer-led-using a rigorous effectiveness-implementation trial. The project applies a reciprocal innovation approach, using insights from Kenya to inform U.S. strategies for scaling community-based autism support.\n\nThe long-term goal is to reduce disparities in autism care by creating scalable, low-cost, caregiver-driven models. A Community Advisory Panel will guide the research to ensure relevance and impact. This initiative represents a transformative step toward equitable autism services across global and U.S. settings.",[29,28,30],[354,355,356,357,358,359],"Caregiver Intervention","Training","Children","Low Resource","Disability","Early Intervention","2025-11-21",{"date":362,"type":40},"2025-12-02",{"date":364,"type":22},"2026-07-01",{"date":366,"type":22},"2030-06-01",{"name":368,"class":47},"Indiana University",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":57,"sex":17,"minAge":248,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":386,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":48},"100454185","mri-eye-tracking-pairing-a-tool-for-assessing-social-cognition-in-children-with-asd-100454185","NCT05194254","MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD","IRM-ET","Inclusion Criteria:\n\nFor the group of people with Autism Spectrum Disorders (experimental group):\n\n* Age between 10 to 20 years old\n* Diagnosis of ASD (CARS) ≥ 30 performed at inclusion\n* IQ test evaluation (regardless of the result) performed by a trained psychologist\n* Obtaining informed oral and written consent after appropriate information\n* Obtaining informed oral and written consent from the legal guardian after information\n* Be affiliated with social security\n* No contraindication to magnetic resonance imaging\n\nFor the TD (Typical Development) group of people (control group):\n\n* Age between 10 to 20 years old\n* Diagnosis of ASD (CARS) \\\u003C30 performed at inclusion\n* IQ test evaluation (regardless of the result) performed by a trained psychologist\n* Obtaining informed oral and written consent after appropriate information\n* Obtaining informed oral and written consent from the legal guardian after information\n* Be affiliated with social security\n* No contraindication to magnetic resonance imaging\n\nExclusion Criteria:\n\nFor all groups:\n\n* Age outside the range 10 to 20 years\n* Person with a contraindication to MRI (including claustrophobia, pace maker, neurosurgical clips, vascular clips, heart valves, ventriculoperitoneal valves, cochlear implant, neurostimulator, intraocular metal shards, joint prosthesis, etc.)\n* Person suffering from major obesity (\\> 140 kg) not allowing him to enter the tunnel of the MRI machine (diameter \\\u003C70cm)\n* Pregnant or breastfeeding woman\n* Person under guardianship or guardianship or deprived of liberty by a judicial or administrative decision\n\nFor TD people (control group):\n\n* Person with psychiatric disorders such as attention disorder with or without hyperactivity, depression, bipolar disorder and schizophrenia.\n* Person with a neurological history such as epilepsy and \u002F or neurovascular accident.","20 Years",{"count":378,"type":22},68,[25],"Most studies use static visual percepts that are less representative of joint attention versus an ecological environment. This has the consequence of decreasing the perception of an interaction with a social partner, which is an essential step in achieving joint attention. The originality of this study is to improve the design of visual percepts (in the form of video) in order to mimic an ecological environment as much as possible by using MRI-ET coupling. The second originality of this study is the longitudinal exploration of the neurodevelopment of social cognition in autistic children. Studies by the Redcay and Oberwelland teams observe different activations at different ages. The hypothesis is that the perception of joint attention varies over time in people with ASD. To date, there are no studies to determine the influence of childhood neurodevelopment in autistic people on the perception of joint attention. It would be unprecedented to use the MRI-ET pairing as a tool for assessing social cognition as a function of the development of children with ASD.",[30,382,383,384,385],"Functional Magnetic Resonance Imaging","Eye Tracking","Social Cognition","Joint Attention",[30,387,383,388,389],"Functional magnetic resonance imaging","social cognition","joint attention","2025-05-22",{"date":392,"type":40},"2025-05-28",{"date":394,"type":40},"2022-01-04",{"date":396,"type":22},"2025-06",{"name":398,"class":47},"Centre Hospitalier Universitaire, Amiens",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":17,"minAge":272,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100574632","electrocardiographic-and-electrophysiologic-changes-after-percutaneous-closure-of-atrial-septal-defect-100574632","NCT06761807","Electrocardiographic and Electrophysiologic Changes After Percutaneous Closure of Atrial Septal Defect","Inclusion Criteria:\n\n* All patients presented with secundum ASD eligible for percutaneous transcatheter ASD closure at Assiut university heart hospital\n\nExclusion Criteria:\n\n* No exclusion",{"count":406,"type":22},65,[25],"Primary outcomes :\n\nDetermining the incidence of SAN and AVN dysfunction before and after percutaneous ASD closure Comparing ECG and EP parameters of SAN and AVN before and after percutaneous ASD closure\n\nSecondary outcomes :\n\nAssessing clinical, echocardiographic and procedural risk factors affecting the AVN function after ASD closure device implantation Determining the incidence of supraventricular arrhythmia inducibility before and after percutaneous ASD closure",[30,410],"Brady Arrythmia",[30,412,413],"EPD","Brady arrythmia","2025-01-06",{"date":416,"type":40},"2025-01-07",{"date":418,"type":22},"2025-01-20",{"date":420,"type":22},"2027-11-02",{"name":422,"class":47},"Assiut University",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":57,"sex":17,"minAge":429,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":432,"conditions":433,"keywords":437,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":451},"100244520","natural-history-study-of-individuals-with-autism-and-germline-heterozygous-pten-mutations-100244520","NCT02461446","Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations","Inclusion Criteria\n\n* Individuals above the age of 18 months old at the time of consent who have documentation of a clinical diagnosis of autism spectrum disorder and\u002For a verified PTEN mutation from a medical or mental health professional for inclusion in the PTEN ASD, PTEN no-ASD or ASD macrocephaly groups.\n* Macrocephaly (head circumference greater than or equal to 98th percentile) for inclusion in the ASD macrocephaly group.\n* For youths, consent from parents or legal guardian. For adults, consent from self or legal guardian.\n* Youths who are able (some young or severely impaired participants may not be able to provide assent) will be asked to provide assent as per IRB guidelines.\n* Families with multiple children who meet the above inclusion criteria will be permitted to have as many children participate as they wish. A separate consent form will be filled out for each child enrolled in the study.\n* Primary communicative language must be English\n\nExclusion Criteria\n\n* Unwilling or unable to comply with study procedures and assessments\n* Clinically significant medical disease that would prohibit participation in the study procedures.\n* For subjects ELIGIBLE FOR OPTIONAL imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants\u002Fnon-compatible medical devices or medical conditions, including vagus nerve stimulator.\n* For subjects ELIGIBLE FOR EEG\u002FERP biomarker assessment: contraindications to EEG\u002FERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP\u002FVEP equipment. Under age 2 or over 11 at the time of enrollment.","18 Months",{"count":431,"type":22},170,"The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.",[434,30,28,435,436],"PTEN","Macrocephaly","PTEN Hamartoma Tumor Syndrome",[438,439,440,30,28,435,436,434,441],"germline heterozygous PTEN mutations","MRI","10q23.3","EEG","2024-10-24",{"date":444,"type":40},"2024-10-26",{"date":446,"type":4},"2015-05",{"date":448,"type":22},"2026-12",{"name":450,"class":47},"Boston Children's Hospital",5,{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":57,"sex":17,"minAge":19,"maxAge":139,"enrollmentInfo":459,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":461,"conditions":462,"keywords":469,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":48},"100517081","lower-urinary-tract-symptoms-and-school-functioning-in-children-100517081","NCT06012903","Lower Urinary Tract Symptoms and School Functioning in Children","Epidemiological Study of Lower Urinary Tract Symptoms and School Functioning in Children in Regular Elementary School","Inclusion Criteria:\n\n* Children in 4th-6th grade\n* Parents whose children are in grades 1-6\n* Teachers responsible for teaching children in grades 1-6\n* Children who attend regular primary education\n* Capable of speaking \\& comprehending Dutch\n\nExclusion Criteria:\n\n* High school students\n* home-schooled children\n* children who attend special needs education\n* Language barrier to understanding Dutch",{"count":460,"type":22},250,"Children in primary school often suffer from lower urinary tract symptoms (LUTS), which may negatively impact their overall well-being. Co-occurring neurodevelopmental disorders (NDDs) can adversely affect children as well and can cause restrictions in their daily life, especially in their school-environment.\n\nThe goal of this observational study is to identify the prevalence of LUTS in Flemish primary school children.The main questions it aims to answer are:\n\n* How prevalent are LUTS in regular primary education?\n* Is there a relation with well-being in school environment?\n* Is there an influence of co-occuring NDDs? Children, parents and teachers will be asked to fill in questionnaires related to this research question.",[463,464,465,69,30,466,467,468],"Lower Urinary Tract Symptoms","Neurodevelopmental Disorders","Incontinence, Urinary","Developmental Coordination Disorder","Child Development","Quality of Life",[470,471,472,473,474,475],"lower urinary tract symptoms","Quality of life","Pediatrics","neurodevelopmental disorders","VSSDES","DCD-Q","2024-07-12",{"date":478,"type":40},"2024-07-15",{"date":480,"type":40},"2022-10-06",{"date":482,"type":22},"2025-06-06",{"name":484,"class":47},"University Hospital, Ghent"]